美国真实世界证据(RWE)解决方案市场:按组件(数据集(临床,计费,药房,集成),服务),应用程序(市场准入,肿瘤学,神经病学),用户(製药,医疗保健交付人)预测~2029

美国真实世界证据 (RWE) 解决方案的市场规模预计在 2022 年至 2029 年间以 13.1% 的复合年增长率增长，到 2029 年达到 22.2 亿美元。推动市场增长的关键因素包括慢性病和传染病发病率的增加、药物开发的延迟和相关的开发成本增加、对个性化医疗、基于体积价值的医疗的日益关注以及大数据的迅速崛起在医疗保健。

本报告研究了美国真实世界证据 (RWE) 解决方案市场，其中包括市场概况、市场规模和预测、趋势、驱动因素和限制、竞争格局、组件、应用程序和终端它提供用户特定的分析，公司简介等。

内容

第一章介绍

• 市场定义
• 市场生态系统
• 货币

第二章研究方法

• 研究过程
• 数据收集和验证
  • 二次调查
  • 初步调查
• 市场评估
  • 市场规模预测
  • 市场份额分析
• 调查先决条件
• 调查限制

第 3 章执行摘要

第 4 章市场洞察

• 市场概览
• 驱动程序
  • 慢性病和传染病负担上升
  • 对个性化医疗的兴趣日益浓厚
  • 药物开发延迟并随之增加开发成本
  • 转向基于价值的护理
  • 大数据在医疗保健领域的快速扩张
• 限制因素
  • 不愿依赖真实世界的研究
• 机会
  • 对端到端 RWE 服务的兴趣日益浓厚
  • RWE 越来越多地采用可穿戴设备和人工智能
• 任务
  • 缺乏开发 RWE 的标准化方法
• 主要市场趋势
  • 在药物开发和商业化中扩大 RWE 的采用
  • 合併数量增加
  • 基于 RWE 改善患者治疗效果并创造价值
• 评估 COVID-19 对美国真实世界证据 (RWE) 解决方案市场的影响

第 5 章监管分析:美国真实世界证据 (RWE) 解决方案市场

第 6 章定价模型（EMR/基因组学/集成数据集）

• 简介
• 按患者记录付费（基于数量的定价）
• 即用即付系统（基于价值的定价）
• 年费

第 7 章。美国真实世界证据 (RWE) 解决方案市场:按组件

• 简介
• 数据集
  • 异构数据集
  • 综合数据集
• 咨询和分析

第 8 章。美国真实世界证据 (RWE) 解决方案市场:按应用分类

• 简介
• 确定市场准入和赎回/覆盖范围
• 药物开发和批准
  • 肿瘤学
  • 神经科
  • 免疫学
  • 心血管疾病
  • 其他治疗领域
• 医疗器械的开发和审批
• 上市后监督
• 其他

第 9 章。美国真实世界证据 (RWE) 解决方案市场:按最终用户分类

• 简介
• 製药、生物技术和医疗器械公司
• 医疗费用支付方
• 医疗保健提供者
• 其他

第 10 章竞争格局

• 简介
• 主要增长战略
• 竞争基准
• 市场份额分析（2020 年）
  • IQVIA Holdings, Inc.
  • 图标公司
  • PPD, Inc.

第 11 章公司简介（业务概览、财务概览、解决方案组合、战略发展）

• Anthem, Inc.
• Clinigen Group plc.
• Cognizant Technology Solutions Corporation
• ICON plc
• IQVIA HOLDINGS INC.
• Oracle Corporation
• PAREXEL International Corporation
• PerkinElmer, Inc.
• PPD, Inc.
• SAS Institute Inc.
• UnitedHealth Group Incorporated
• Flatiron Health, Inc.

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)- Forecast to 2029

The U.S. RWE solutions market is expected to grow at a CAGR of 13.1% from 2022 to 2029 to reach $2.22 billion by 2029

Following a thorough secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities

Growing incidence of chronic & infectious diseases, delays in drug development and the subsequent increase in development costs, rising focus towards personalized healthcare, a shift from volume to value-based care, and rapidly growing big data in healthcare are the key factors driving steady growth in the U.S. RWE solutions market. Further, significant opportunities for existing market players and new entrants are provided by rising focus on end-to-end RWE services, and rising adoption of wearable devices and AI in RWE

Based on component, in 2022, the datasets segment is expected to command the largest share in the market. Real-world data (RWD) are derived from various sources associated with outcomes in a heterogeneous patient population in real-world settings. Datasets are present in a secondary format on which retrospective studies are conducted to generate real-world evidence. This real-world evidence provides meaningful insights into unmet needs and the clinical and economic impacts on patients and healthcare systems. It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials.

Based on application, the drug development & approvals segment is expected to show the fastest growth rate in the forecast period. Factors attributing towards the growth of this segment are increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, and increasing investments by biopharmaceutical companies in R&D.

In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Based on end user, the pharmaceutical & medical device companies segment is expected to show the fastest growth rate in the forecast period. The growth of this segment is primarily attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

The cost of developing a new drug was more than ~USD 2,600 million in 2020 compared to USD 802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face.

The key companies operating in the U.S. RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA HOLDINGS INC. (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

Scope of the Report

U.S. RWE Solutions Market, by Component

• Datasets
• Disparate Datasets
• EMR/EHR/Clinical Data
• Claims & Billing Data
• Pharmacy Data
• Product/Disease Registries Data
• Other Disparate Datasets
• Integrated Datasets
• Consulting and Analytics

(Note - Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

U.S. RWE Solutions Market, by Application

• Market Access & Reimbursement/Coverage Decisions
• Drug Development & Approvals
• Oncology
• Neurology
• Immunology
• Cardiovascular Diseases
• Other Therapeutic Areas
• Post Market Surveillance
• Medical Device Development & Approvals
• Clinical and Regulatory Decision-Making

(Note - Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)

U.S. RWE Solutions Market, by End User

• Pharmaceutical, Biotechnology, and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users

(Note - Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Ecosystem
• 1.3. Currency

2. Research Methodology

• 2.1. Research Process
• 2.2. Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research
• 2.3. Market Assessment
  • 2.3.1. Market Size Estimation
    • 2.3.1.1. Bottom-Up Approach
    • 2.3.1.2. Top-Down Approach
    • 2.3.1.3. Growth Forecast
  • 2.3.2. Market Share Analysis
• 2.4. Assumptions for the Study
• 2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

• 4.1. Market Overview
• 4.2. Drivers
  • 4.2.1. Growing Burden of Chronic and Infectious Diseases
  • 4.2.2. Rising Focus Towards Personalized Healthcare
  • 4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
  • 4.2.4. Shift Towards Value-Based Care
  • 4.2.5. Rapidly Growing Big Data in Healthcare
• 4.3. Restraints
  • 4.3.1. Reluctance to Rely on Real-World Studies
• 4.4. Opportunities
  • 4.4.1. Rising Focus on End-to-End RWE Services
  • 4.4.2. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
• 4.5. Challenges
  • 4.5.1. Lack of Standardized Methodologies to Develop RWE
• 4.6. Key Market Trends
  • 4.6.1. Growing Adoption of RWE in Drug Development and Commercialization
  • 4.6.2. Rising Number of Consolidations
  • 4.6.3. Improved Patient Outcomes and Value Creation from Real-World Evidence
• 4.7. Impact Assessment of COVID-19 on the U.S. RWE Solutions Market

5. Regulatory Analysis - U.S. Real-World Evidence (RWE) Solutions Market

6. Pricing Models (EMR/Genomic/Integrated Datasets)

• 6.1. Introduction
• 6.2. Pay Per Patient Record (Volume-Based Pricing)
• 6.3. Pay Per Usage (Value-Based Pricing)
• 6.4. Annual Subscription

7. U.S. Real-World Evidence Solutions Market, by Component

• 7.1. Introduction
• 7.2. Datasets
  • 7.2.1. Disparate Datasets
    • 7.2.1.1. EMR/EHR/Clinical Data
    • 7.2.1.2. Claims & Billing Data
    • 7.2.1.3. Pharmacy Data
    • 7.2.1.4. Product/Disease Registries Data
    • 7.2.1.5. Other Disparate Datasets
  • 7.2.2. Integrated Datasets
• 7.3. Consulting & Analytics

8. U.S. Real-World Evidence Solutions Market, by Application

• 8.1. Introduction
• 8.2. Market Access & Reimbursement/Coverage Decisions
• 8.3. Drug Development & Approvals
  • 8.3.1. Oncology
  • 8.3.2. Neurology
  • 8.3.3. Immunology
  • 8.3.4. Cardiovascular Diseases
  • 8.3.5. Other Therapeutic Areas
• 8.4. Medical Device Development & Approvals
• 8.5. Post-Market Surveillance
• 8.6. Other Applications

9. U.S. Real-World Evidence Solutions Market, by End User

• 9.1. Introduction
• 9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
• 9.3. Healthcare Payers
• 9.4. Healthcare Providers
• 9.5. Other End Users

10. Competitive Landscape

• 10.1. Introduction
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Market Share Analysis (2020)
  • 10.4.1. IQVIA Holdings, Inc. (U.S.)
  • 10.4.2. ICON plc (Ireland)
  • 10.4.3. PPD, Inc. (U.S.)

11. Company Profiles (Business Overview, Financial Overview, Solution Portfolio, Strategic Developments)

• 11.1. Anthem, Inc.
• 11.2. Clinigen Group plc.
• 11.3. Cognizant Technology Solutions Corporation
• 11.4. ICON plc
• 11.5. IQVIA HOLDINGS INC.
• 11.6. Oracle Corporation
• 11.7. PAREXEL International Corporation
• 11.8. PerkinElmer, Inc.
• 11.9. PPD, Inc.
• 11.10. SAS Institute Inc.
• 11.11. UnitedHealth Group Incorporated
• 11.12. Flatiron Health, Inc.

List of Tables

• Table 1 U.S. Real-World Evidence Solutions Market Drivers: Impact Analysis (2022-2029)
• Table 2 Total Per-Study Cost (In Usd Million), by Phase and Therapeutic Area
• Table 3 Sources of Healthcare Data
• Table 4 U.S. Real-World Evidence Solutions Market Restraints: Impact Analysis (2022-2029)
• Table 5 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
• Table 6 U.S. Real-World Evidence Solutions Market Size, by Component, 2012-2029 (USD Million)
• Table 7 U.S. Real-World Evidence Datasets Market Size, by Type, 2020-2029 (USD Million)
• Table 8 U.S. RWE Disparate Datasets Market Size, by Type, 2020-2029 (USD Million)
• Table 9 U.S. Real-World Evidence Solutions Market Size, by Application, 2020-2029 (USD Million)
• Table 10 U.S. RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
• Table 11 Estimated Number of New Cancer Cases in the U.S. (2019-2023)
• Table 12 Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
• Table 13 Other Therapeutic Areas: Drugs in the R&D Pipeline
• Table 14 U.S. RWE Solutions Market Size, by End User, 2020-2029 (USD Million)
• Table 15 Recent Developments, by Company, 2018-2022

List of Figures

• Figure 1 Key Stakeholders
• Figure 2 Research Process
• Figure 3 Key Secondary Sources
• Figure 4 Primary Research Techniques
• Figure 5 Key Executives Interviewed
• Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
• Figure 7 Market Size Estimation
• Figure 8 U.S. Real-World Evidence Solutions Market, by Component, 2022 Vs. 2029 (USD Million)
• Figure 9 U.S. Real-World Evidence Solutions Market, by Application, 2022 Vs. 2029 (USD Million)
• Figure 10 U.S. Real-World Evidence Solutions Market, by End User, 2022 Vs. 2029 (USD Million)
• Figure 11 Market Dynamics
• Figure 12 Number of People in the U.S. With Chronic Conditions (2000-2030)
• Figure 13 Percentage of Personalized Medicines Approved (2015-2020)
• Figure 14 U.S. Real-World Evidence Solutions Market Size, by Component, 2022-2029 (USD Million)
• Figure 15 U.S.: Number of E-Prescriptions, 2013-2020 (Billions)
• Figure 16 U.S. Real-World Evidence Solutions Market Size, by Application, 2022-2029 (USD Million)
• Figure 17 Dalys of Neurological Disorders in the U.S., 2010-2021 (In Thousands)
• Figure 18 U.S.: Hepatitis A Virus (HAV) Infections, 2013-2020
• Figure 19 U.S. Real-World Evidence Solutions Market Size, by End User, 2022-2029 (USD Million)
• Figure 20 U.S. Pharmaceutical R&D Spending, 1980-2019 (USD Billion)
• Figure 21 Key Growth Strategies Adopted by Leading Players (2018-2022)
• Figure 22 U.S. Real-World Evidence Solutions: Competitive Benchmarking
• Figure 23 Market Share Analysis: U.S. Real-World Evidence Solutions Industry (2021)
• Figure 24 Anthem, Inc.: Financial Overview (2021)
• Figure 25 Clinigen Group plc: Financial Overview (2021)
• Figure 26 Cognizant Technology Solutions Corporation: Financial Overview (2021)
• Figure 27 ICON plc: Financial Overview (2021)
• Figure 28 IQVIA HOLDINGS INC.: Financial Overview (2021)
• Figure 29 Oracle Corporation: Financial Overview (2021)
• Figure 30 PerkinElmer, Inc.: Financial Overview (2022)
• Figure 31 PPD, Inc.: Financial Overview (2020)
• Figure 32 SAS Institute Inc.: Financial Overview (2021)
• Figure 33 UnitedHealth Group Incorporated.: Financial Overview (2021)